“The findings from the SYMON-I study suggest that IL-6 measured in the emergency department may be associated with subsequent organ dysfunction in patients with sepsis and septic shock. These data ...

CARSON CITY, Nev., March 12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and ...

The Muscular Dystrophy Association (MDA) concluded its 2026 MDA Clinical & Scientific Conference yesterday, convening over 2,400 attendees from 40 countries to help shape the future of neuromuscular ...

National Conference is Road Safety GB’s flagship event, with the 2026 edition – the 16 th – being held at The Queens Hotel, Leeds on 24-25 November 2026. For the past three years around 400 road ...

PITTSBURGH, PA, UNITED STATES, March 6, 2026 /EINPresswire.com/ -- For more than 25 years, Cribs for Kids has worked ...

The CitiesAlive 2026 in Brooklyn this September Call for Proposals & Research Papers is Open & the Deadline to Submit is ...

Building on the recent U.S. FDA Fast Track Designation for AJ201 (Rosolutamide) and encouraging Phase 2 clinical results, AnnJi presented two scientific abstracts spanning translational transcriptomic ...

Produced by SAF Magazine and organized by BBI International in Collaboration with CAAFI TACOMA, WA, UNITED STATES, ...

Phase I Clinical Trial Evaluating Safety, Tolerability, and Early Activity of Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF-Altered Solid Tumors or NRAS-Mutant Melanoma We ...

Belzutifan is advancing in RCC, with LITESPARK-011 showing PFS/ORR benefit with lenvatinib post–PD-(L)1, and LITESPARK-022 improving adjuvant DFS with pembrolizumab. Perioperative enfortumab vedotin ...

CARSON CITY, Nev., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and ...

Each abstract program is designed to highlight excellence across various stages of dermatologic research. Please refer to the tabs below for detailed information on each abstract program, including ...